BI-D1870

PubMed: 17040210      Biochem J

(A) HEK-293 cells that had been deprived of serum for 16 h, were incubated in the absence or presence of 10 μM BI-D1870 for the indicated times, then stimulated with 400 ng/ml PMA (TPA) for 20 min. The cells were lysed and the lysates were immunoblotted with the indicated antibodies as described in the Materials and methods section. (B) As in (A), except that cells were incubated for 30 min with the indicated concentrations of BI-D1870 prior to stimulation with PMA. Similar results were obtained in two separate experiments.

PubMed: 28415756      Oncotarget

Western Blot analysis of RSK activity (PS102-YB-1, PS112-Bad) of double resistant SKMel28 RR after treatment with increasing concentrations of BI-D1870 for 24 h. GAPDH was detected as a loading control.

PubMed: 25395420      Blood

(B) H929 cells were incubated with BI-D1870 (BI, 3 μM) at indicated time points, followed by immunoblotting analysis. (C) JJN3 cells were incubated with BI-D1870 at indicated doses for 6 hours, followed by immunoblotting analysis.

PubMed: 17040210      Biochem J

(A) HEK-293 cells that had been deprived of serum for 16 h, were incubated in the absence or presence of 10 μM BI-D1870 for the indicated times, then stimulated with 400 ng/ml PMA (TPA) for 20 min. The cells were lysed and the lysates were immunoblotted with the indicated antibodies as described in the Materials and methods section. (B) As in (A), except that cells were incubated for 30 min with the indicated concentrations of BI-D1870 prior to stimulation with PMA. Similar results were obtained in two separate experiments.

PubMed: 28415756      Oncotarget

Western Blot analysis of RSK activity (P(S102)-YB-1, P(S112)-Bad) of double resistant SKMel28 RR after treatment with increasing concentrations of BI-D1870 for 24 h. GAPDH was detected as a loading control.

PubMed: 25395420      Blood

(B) H929 cells were incubated with BI-D1870 (BI, 3 μM) at indicated time points, followed by immunoblotting analysis. (C) JJN3 cells were incubated with BI-D1870 at indicated doses for 6 hours, followed by immunoblotting analysis.

PubMed: 25002506      Proc Natl Acad Sci U S A

A375 cells treated as in E were imaged using immunofluorescence microscopy. Cells were stained with anti-PDCD4 antibodies to visualize endogenous PDCD4, phalloidin to visualize F-actin, and DAPI to visualize nuclei.

PubMed: 25002506      Proc Natl Acad Sci U S A

A375 cells treated as in (E) were imaged using immunofluorescence microscopy. Cells were stained with anti-PDCD4 antibodies to visualize endogenous PDCD4, phalloidin to visualize F-actin, and DAPI to visualize nuclei.

PubMed: 28415756      Oncotarget

(D–F) Cell viability (MUH assay) of double resistant melanoma cells after a 72 h-treatment with increasing concentrations of vemurafenib (D), trametinib (E) or vemurafenib and trametinib (F), as well as of BI-D1870 and the combination of MAPK inhibitors and BI-D1870 (n = 6; mean ± SD). Signals were normalized to the DMSO-treated controls.

PubMed: 28415756      Oncotarget

(D–F) Cell viability (MUH assay) of double resistant melanoma cells after a 72 h-treatment with increasing concentrations of vemurafenib (D), trametinib (E) or vemurafenib and trametinib (F), as well as of BI-D1870 and the combination of MAPK inhibitors and BI-D1870 (n = 6; mean ± SD). Signals were normalized to the DMSO-treated controls.